AA Financial Advisors LLC Sells 2,787 Shares of Astrazeneca Plc $AZN

AA Financial Advisors LLC trimmed its position in Astrazeneca Plc (NYSE:AZN) by 46.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,268 shares of the company’s stock after selling 2,787 shares during the quarter. AA Financial Advisors LLC’s holdings in Astrazeneca were worth $645,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership raised its holdings in Astrazeneca by 552.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock valued at $973,603,000 after acquiring an additional 4,697,895 shares during the period. Bank of Montreal Can grew its position in shares of Astrazeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares in the last quarter. Citigroup Inc. raised its stake in Astrazeneca by 65.3% during the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock valued at $1,080,160,000 after purchasing an additional 2,431,890 shares during the period. Holocene Advisors LP raised its stake in Astrazeneca by 41.8% during the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after purchasing an additional 1,807,565 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its holdings in Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after purchasing an additional 1,790,874 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Up 1.4%

Shares of AZN opened at $185.61 on Friday. The stock has a market capitalization of $287.86 billion, a price-to-earnings ratio of 27.87, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The business’s 50 day simple moving average is $184.90 and its 200-day simple moving average is $186.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, equities analysts expect that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.